112 related articles for article (PubMed ID: 24262315)
21. Reduction of the number of mice used for potency testing of human and animal rabies vaccines.
Bruckner L; Palatini M; Ackermann M; Müller HK; Kihm U
Experientia; 1988 Oct; 44(10):853-7. PubMed ID: 3181371
[TBL] [Abstract][Full Text] [Related]
22. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.
Thraenhart O; Ramakrishnan K
J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705
[TBL] [Abstract][Full Text] [Related]
23. Use of ELISA for in vitro potency test of rabies vaccines for animal use.
Gamoh K; Senda M; Itoh O; Muramatsu M; Hirayama N; Koike R; Endoh YS; Minamoto N
Biologicals; 1996 Jun; 24(2):95-101. PubMed ID: 8889055
[TBL] [Abstract][Full Text] [Related]
24. Competitive ELISA using a rabies glycoprotein-transformed cell line to semi-quantify rabies neutralizing-related antibodies in dogs.
Zhang S; Liu Y; Zhang F; Hu R
Vaccine; 2009 Mar; 27(15):2108-13. PubMed ID: 19356613
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use.
Korimbocus J; Dehay N; Tordo N; Cano F; Morgeaux S
Vaccine; 2016 Jun; 34(28):3310-6. PubMed ID: 27151880
[TBL] [Abstract][Full Text] [Related]
26. A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use.
Krämer B; Kamphuis E; Hanschmann KM; Milne C; Daas A; Duchow K
Biologicals; 2013 Nov; 41(6):400-6. PubMed ID: 24144483
[TBL] [Abstract][Full Text] [Related]
27. Novel monoclonal antibodies that bind to wild and fixed rabies virus strains.
Zanluca C; Aires LR; Mueller PP; Santos VV; Carrieri ML; Pinto AR; Zanetti CR
J Virol Methods; 2011 Jul; 175(1):66-73. PubMed ID: 21536074
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a potency test by ELISA for a rabies vaccine for animal use in Japan.
Gamoh K; Shimazaki Y; Senda M; Makie H; Itoh O; Muramatsu M; Hirayama N; Hatakeyama H
J Vet Med Sci; 2003 Jun; 65(6):685-8. PubMed ID: 12867727
[TBL] [Abstract][Full Text] [Related]
29. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2.
Patial S; Chaturvedi VK; Rai A; Saini M; Chandra R; Saini Y; Gupta PK
Vaccine; 2007 May; 25(20):4020-8. PubMed ID: 17391817
[TBL] [Abstract][Full Text] [Related]
30. Potency of veterinary rabies vaccines in The Netherlands: a case for continued vigilance.
Rooijakkers EJ; Nieuwenhuijs JH; Vermeulen AA; van Steenis G; Osterhaus AD
Vet Q; 1996 Dec; 18(4):146-50. PubMed ID: 8972063
[TBL] [Abstract][Full Text] [Related]
31. The use of various immunochemical, biochemical and biological methods for the analysis of rabies virus production in tissue cultures.
Adamovicz P; Aguilon F; David A; Le Fur R; Mazert MC; Perrin P; Reculard P; Sureau P
Dev Biol Stand; 1983; 55():191-7. PubMed ID: 6677532
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
[TBL] [Abstract][Full Text] [Related]
33. Single radial immunodiffusion assays for the standardization of the antigenic content of rabies vaccines.
Ferguson M; Seagroatt V; Schild GC
Dev Biol Stand; 1986; 64():81-6. PubMed ID: 3098607
[TBL] [Abstract][Full Text] [Related]
34. Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay.
Lafon M; Perrin P; Versmisse P; Sureau P
J Biol Stand; 1985 Oct; 13(4):295-301. PubMed ID: 3902842
[TBL] [Abstract][Full Text] [Related]
35. Use of the single radial immunodiffusion test as a replacement for the NIH mouse potency test for rabies vaccine.
Fitzgerald EA; Needy CF
Dev Biol Stand; 1986; 64():73-9. PubMed ID: 3098606
[TBL] [Abstract][Full Text] [Related]
36. Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57.
Duan Y; Gu T; Zhang X; Jiang C; Yuan R; Li Z; Wang D; Chen X; Wu C; Chen Y; Wu Y; Kong W
Mol Immunol; 2014 Jun; 59(2):136-41. PubMed ID: 24598312
[TBL] [Abstract][Full Text] [Related]
37. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.
Bakker AB; Marissen WE; Kramer RA; Rice AB; Weldon WC; Niezgoda M; Hanlon CA; Thijsse S; Backus HH; de Kruif J; Dietzschold B; Rupprecht CE; Goudsmit J
J Virol; 2005 Jul; 79(14):9062-8. PubMed ID: 15994800
[TBL] [Abstract][Full Text] [Related]
38. An ELISA-based antigenicity test of rabies recombinant glycoprotein cannot predict its protective potency in vivo.
Volokhov DV; Fry AM; Furtak V; Jones RM; Musiychuk K; Norikane J; Green BJ; Srinivas GB; Streatfield SJ; Yusibov V
Mol Cell Probes; 2022 Jun; 63():101815. PubMed ID: 35364264
[TBL] [Abstract][Full Text] [Related]
39. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice.
Kaur M; Saxena A; Rai A; Bhatnagar R
FASEB J; 2010 Jan; 24(1):173-83. PubMed ID: 19741168
[TBL] [Abstract][Full Text] [Related]
40. Rabies vaccine response measurement is assay dependent.
Moore SM; Pralle S; Engelman L; Hartschuh H; Smith M
Biologicals; 2016 Nov; 44(6):481-486. PubMed ID: 27726931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
